Imigran (Sumatriptan Succinate)

Sumatriptan, the active ingredient in Imigran, binds selectively to 5‑HT1B and 5‑HT1D receptors. This causes constriction of dilated cranial blood vessels and blocks release of inflammatory neuropeptides, interrupting the migraine cascade and providing pain relief.

The dose of Imigran is determined by the prescribing clinician based on the patient’s condition and response. Typical oral tablets are available in standard strengths, and the prescriber will advise the appropriate amount and timing for each migraine episode.

Safety data for sumatriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Imigran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imigran belongs to the triptan class, which provides targeted serotonin‑mediated vasoconstriction. Compared with non‑specific analgesics such as NSAIDs, triptans often achieve faster and more complete headache relief but require screening for cardiovascular risk. Other triptans have similar efficacy with varying onset times and side‑effect profiles.

Imigran tablets should be stored at ambient temperature below 25 °C, in their original packaging, and protected from moisture. Keep the product out of reach of children and avoid exposure to excessive heat or direct sunlight.

Imigran is taken orally as a whole tablet with a glass of water. It should be swallowed whole and not chewed or crushed. The tablet is usually taken at the onset of migraine symptoms, as directed by the prescribing clinician.

Serious risks include serotonin syndrome when combined with other serotonergic agents, coronary vasospasm leading to chest pain or heart attack, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience severe chest discomfort, difficulty breathing, or signs of an allergic reaction.

Imigran is contraindicated in patients with uncontrolled hypertension, significant cardiovascular disease (including coronary artery disease, arrhythmias, or peripheral vascular disease), a history of stroke or transient ischemic attack, and in those taking MAO inhibitors within the past 14 days. It should also be avoided in patients with known hypersensitivity to sumatriptan.